Planning a Clinical Trial? Here’s why Data Management matters

Data from therapy development, especially those involving cells, can quickly mushroom into an unmanageable pile in the lab — what happens when you move to the clinic? We sat down with Venn Life Sciences to discuss effective strategies in data management that might benefit companies looking to bring a therapy like Tregs to market.

Cell therapies are one of the major trends in biotech, and they’re being investigated as a therapy for everything from cancer to chronic inflammation. Say you’re a company looking to leverage T-cells, the ‘soldiers of the immune, if all goes well, you might succeed in finding a cure in the lab, but what happens when you scale up for clinical trials? From their PhD work, scientists are trained to manage laboratory-scale datasets, but the industrial expansion could pose a daunting challenge, especially when it comes to cell therapies.

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data). 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Open Orphan Plc

More articles like this

Open Orphan Plc

Open Orphan Distribution in Specie and Notice of Results

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that, further to previous announcements, it proposes to make a

Open Orphan Plc

End-to-end Drug Development & Clinical Research services

Venn Life Sciences is an Integrated Drug Development Partner offering aunique combination of drug development expertise and clinical trialdesign and management. This enables us to create, plan and execute drugand medical device development programs effectively and seamlessly forour

Open Orphan Plc

Planning a Clinical Trial? – Think Smart Design

By using smart designs, sponsors can save time and money while optimizing the knowledge accrued during the development of their products. “Traditional” study designs and statistical methodology do not allow changing the main features of a study protocol

Open Orphan Plc

Venn Life Sciences

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses

Open Orphan Plc

Accelerated regulatory pathway for pandemic vaccines

Vaccines form an important part of the combat against the current COVID-19 health crisis. Getting a range of effective vaccines to the market quickly will be essential if we are ever to “return to normal”. Following the landmark

Open Orphan Plc

Open Orphan receives Court approval for the reduction of capital

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation and a world leader in vaccine and antiviral testing using human challenge clinical trials, has confirmed that, following its announcement on 13 April 2021, it has